Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 237236
Licensee shall have the right to grant sublicenses.
PADREÂ® shall mean a peptide capable of binding antigen binding sites on major histocompatibility complex (MHC) molecules encoded by substantially all alleles of a DR locus, including, without limitation, a composition comprising a peptide recited in the claims of United States Patent Application Serial No. 08/121,101 and any patent applications, U.S., international and foreign, that derive priority from such patent application, such as continuing applications and any patents issuing therefrom. Such peptides are also referred to as pan DR binding peptides and include, without limitation, AKXV AA WTLKAAA,using the single letter designation for amino acids, wherein X is cyclohexylalanine or phenylalanine, and other peptides claimed and/or disclosed in the patent applications.
Product shall mean any product that contains, is comprised of or uses PADREÂ® in combination or association with any AutoVacâ„¢ Molecule.
The license is to use PADRE technology for use in connection with their AutoVacâ„¢ technology for controlling autoimmune diseases.
The PADRE technology consists of a family of small (13 amino acid), synthetic proprietary molecules that are potent immunostimulants, meaning that they stimulate the immune response.
IPSCIO Record ID: 212650
â€œLicensed Productâ€ shall mean a prophylactic vaccine containing the Compound co-formulated with the Antigen for delivery by the Delivery Method. No Licensed Product(s) may be developed for the prevention, treatment or control of any cancer nor may any clinical trial be conducted with clinical endpoints of prevention, treatment or control of any cancer.
Patents Claiming Priority to Patent Application Serial No. 08/276,358
IPSCIO Record ID: 277105
This agreement contains both exclusive and non-exclusive grants between the parties.
Licensed Product shall mean a therapeutic or prophylactic vaccine the manufacture. use or sale of which, but for any license granted to Licensee herein, would infringe a Valid Claim of one or more Licensor Patent Rights or one or more Collaboration Patent Rights, or was developed or manufactured using Licensor Know-How.
PADREÂ® Technology shall mean a family of immunostimulatory molecules which when combined with cytotoxic T cell epitopes increase the magnitude and duration of the immune response.